Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

226.56 -0.96 (-0.42%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
33 34 Next >
News headline image
Tesla’s Delayed AGM Draws Investor Heat Amid Musk’s Political Detour And Missed EV Targets ↗
The EV maker’s board had said in April it was delaying its proxy filing due to unresolved matters, including a special committee reviewing Musk’s compensation. 
Via Stocktwits
Topics Government
News headline image
5 Analysts Assess RBC Bearings: What You Need To Know ↗
 
Via Benzinga
News headline image
Integrated Cyber Solutions Welcomes Peter Buckley, Former Head of Cybersecurity at HSBC Canada, to Newly Formed Cyber Future Advisory Board, and Announces Engagement of Investor Relations Personnel, Entrance Into Debt Settlement, Adoption of Omnibus
VANCOUVER, British Columbia – July 8th, 2025 – Integrated Cyber Solutions Inc. (CSE:ICS) (OTCQB:IGCRF) (“ICS” or the “Company”) is pleased to announce the formation of its Cyber Future Advisory Board ,... 
Via PressReach
Topics Artificial Intelligence
News headline image
The 5 Most Interesting Analyst Questions From Lincoln Financial Group’s Q1 Earnings Call
Lincoln Financial Group’s first quarter results prompted a modestly negative market reaction, as investors weighed solid adjusted earnings against a notable miss on operating income versus Wall Street... 
Via StockStory
Topics Earnings
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
Does 1 Top Analyst Know Something About Palantir That the Rest of Wall Street Doesn't? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Tesla Price Target Hiked By Goldman Sachs Despite Q2 Delivery Drop: Analysts Point To ‘Meaningfully Better’ Numbers ↗
Goldman Sachs’ new price target represents a 0.2% downside from TSLA’s closing price on Wednesday. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Bloom Energy Stock Blasted Nearly 30% Higher Last Month ↗
Via The Motley Fool
Topics Artificial Intelligence Energy Government
News headline image
Autoliv Gets Some Wall Street Love With ‘Buy’ Call From Jefferies On Automation, Scale Upsides ↗
The bullish call follows RBC’s recent initiation at ‘Outperform’ and comes as Autoliv maintains its 2025 margin and growth targets. 
Via Stocktwits
Topics Supply Chain
News headline image
RBC Bearings’s Q1 Earnings Call: Our Top 5 Analyst Questions
RBC Bearings’ first quarter saw a positive market response despite missing Wall Street’s revenue target, as strong demand in both its aerospace and industrial segments drove year-on-year sales growth.... 
Via StockStory
Topics Earnings Economy
News headline image
2 Popular AI Stocks to Sell Before They Drop 50% and 69%, According to Wall Street Analysts ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
News headline image
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet ↗
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network. 
Via Stocktwits
News headline image
Benchmark Hikes Tesla Price Target To $475, Says EV Maker Has Advantages Over Waymo In Robotaxi Segment ↗
The new price target represents a 45% upside to the stock’s closing price on Wednesday and follows the EV maker’s successful pilot launch of its robotaxis in Austin over the weekend. 
Via Stocktwits
News headline image
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
News headline image
Kratos Stock Sinks After $484M Offering Priced Below Market; Retail Traders Shrug Off Dilution ↗
The equity raise comes as Kratos expands its role in next-gen defense systems, including a new propulsion partnership with GE Aerospace and growing investor interest driven by bullish analyst... 
Via Stocktwits
News headline image
RBC Analyst Sees Growth Potential In TD Synnex Despite Short-Term Margin Pressures ↗
RBC Capital Markets analyst David Paige reiterated an Outperform rating on TD Synnex and maintained a $145 price forecast. 
Via Benzinga
News headline image
BlackBerry Stock Jumps After Wall Street Hikes Price Targets, But Remains Cautious: Retail’s Exuberant ↗
Analysts are cautiously optimistic on BlackBerry, citing stronger pipeline visibility with QNX and IoT viewed as key growth drivers after its Q1 earnings beat estimates. 
Via Stocktwits
Topics Earnings
News headline image
3 Skyrocketing Artificial Intelligence (AI) Stocks That Can Plummet 71% to 80%, According to Select Wall Street Analysts ↗
Today's high-octane AI stocks could be some of the worst performers over the next year, based on the forecasts of select analysts. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering ↗
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. 
Via Stocktwits
News headline image
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
News headline image
Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial ↗
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. 
Via Stocktwits
News headline image
CarMax Beat Expectations, But Here's What Could Still Hold It Back ↗
RBC maintains Outperform rating on CarMax, raises price target to $81. Q1 earnings beat estimates with strong sales growth, market share gains, and cost management efforts. 
Via Benzinga
Topics Earnings
News headline image
Melissa Sanasie Champions Data Literacy and Storytelling in Marketing
Via Get News
News headline image
Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality ↗
The midstage study hit all its goals, representing a "best case" scenario, according to one analyst. 
Via Investor's Business Daily
News headline image
Circle, GMS Stocks See Big Jump Friday Morning – Here’s What Wall Street Analysts Are Saying ↗
While many analysts on Wall Street have raised their price targets on GMS after The Wall Street Journal’s report that Home Depot may have submitted a competing bid against QXO, RBC Capital said the... 
Via Stocktwits
News headline image
$1000 Invested In RBC Bearings 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
InvestorNewsBreaks – Aegis Capital Corp. Announces Completion of $4.3 Million Public Offering for Stardust Power (NASDAQ: SDST)
Via Investor Brand Network
Topics Retirement
News headline image
Should You Forget Nvidia and Buy This Artificial Intelligence (AI) Stock Right Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Wall Street Turns Bullish On Hinge Health As Analysts Laud Profitable Growth, AI Disruption In MSK Care ↗
Analysts noted Hinge Health’s strong return on investment, rapid automation of care delivery, and profitability milestones as key drivers of their bullish stance. 
Via Stocktwits
Topics Artificial Intelligence
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.